Skip to main content

6 Result(s)

within J. KAERN Remove this filter

and

  1. Article

    Open Access

    Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

    The CALYPSO phase III trial compared CD (carboplatin-pegylated liposomal doxorubicin (PLD)) with CP (carboplatin-paclitaxel) in patients with platinum-sensitive recurrent ovarian cancer (ROC). Overall survival...

    U Wagner, C Marth, R Largillier, J Kaern, C Brown, M Heywood… in British Journal of Cancer (2012)

    Download PDF (219 KB) View Article

  2. Article

    Open Access

    Human germ cell tumours: expression of γ-glutamyl transpeptidase and sensitivity to cisplatin

    Previous studies have shown that the enzyme γ-glutamyl transpeptidase (GGT) is essential for the nephrotoxicity of cisplatin. This study was designed to determine whether GGT activity is necessary for the ther...

    M H Hanigan, H F Frierson Jr, V M Abeler, J Kaern… in British Journal of Cancer (1999)

    Download PDF (530 KB)

  3. No Access

    Article

    Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status

    Cell death after treatment with chemotherapy is exerted by activation of apoptosis, and the p53 protein has been shown to actively participate in this process. This recent focus on TP53 status as a possible de...

    B Smith-Sørensen, J Kaern, R Holm, A Dørum, C Tropé… in British Journal of Cancer (1998)

  4. No Access

    Article

    Cisplatin resistance is associated with reduced interferon-γ-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells

    In ovarian carcinoma cells, the combination of interferon-gamma (IFN-gamma) and cisplatin (cDDP) has been reported to result in a synergistic amplification of antiproliferative activity. To assess whether IFN-...

    C Marth, M Widschwendter, J Kaern, N-P Jørgensen… in British Journal of Cancer (1997)

  5. No Access

    Chapter

    Cellular DNA content: the most important prognostic factor in patients with borderline tumors of the ovary. Can it prevent overtreatment?

    The majority of patients with ovarian borderline tumors and invasive carcinoma stage I have excellent prognosis after surgical removal of the tumor. Nevertheless, nearly all of these patients have received adj...

    J. Kaern, C. G. Tropé, V. Abeler, E. O. Pettersen in Ovarian Cancer 3 (1995)

  6. Article

    HLA antigens and cervical carcinoma

    Å. HELLAND, A. L. BØRRESEN, J. KAERN, K. S. RØNNINGEN, E. THORSBY in Nature (1992)

    Download PDF (1900 KB)